Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Brenntag will supply Food & Nutrition customers in the United States and Canada with Lallemand’s renowned Nutrilife baking enzyme range
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
Subscribe To Our Newsletter & Stay Updated